Market Overview - On August 25, the agricultural processing sector rose by 2.01% compared to the previous trading day, with Yizhi Mohou leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] Stock Performance - Yizhi Mohou (839273) closed at 47.59, with an increase of 8.55% and a trading volume of 96,300 shares, amounting to a transaction value of 445 million [1] - COFCO Sugar (600737) closed at 15.92, up 6.70%, with a trading volume of 1,333,700 shares and a transaction value of 2.087 billion [1] - Oufu Egg Industry (839371) closed at 11.62, increasing by 4.59%, with a trading volume of 93,300 shares and a transaction value of 10.8 million [1] - Morning Light Bio (300138) closed at 14.20, up 4.41%, with a trading volume of 173,500 shares and a transaction value of 242 million [1] - Other notable stocks include ST Langyuan (300175) with a 1.91% increase and a closing price of 5.86, and Jinlongyu (300999) with a 1.77% increase and a closing price of 33.29 [1] Capital Flow - The agricultural processing sector saw a net inflow of 171 million from institutional investors, while retail investors experienced a net outflow of 1.82 billion [2][3] - Major stocks like COFCO Sugar and Jinlongyu had significant capital movements, with COFCO Sugar seeing a net inflow of 156 million from institutional investors [3] - Jinlongyu had a net inflow of 33.81 million from institutional investors, while retail investors withdrew 12.1 million [3]

证券代码：300138 证券简称：晨光生物 公告编号：2025—075 晨光生物科技集团股份有限公司 关于持股 5%以上股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）近日接到公司持股 5%以上股东卢庆国先生通知，获悉其所持有本公司的部分股份质押状态发生了变 动，具体如下： | 股东名 | 是否为控 股股东或 第一大股 | 本次质押数 | 占其所 持股份 | 占公司 总股本 | 是否 为限 | 是否 为补 | 质押起 | 质押到 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 东及其一 | 量（股） | 比例 | 比例 | 售股 | 充质 | 始日 | 期日 | | 用途 | | | 致行动人 | | | | | 押 | | | | | | | | 6,360,000 | 6.48% | 1.32% | 否 | 否 | 2025-08 -21 | 办理解 ...

晨光生物科技集团股份有限公司（以下简称"公司"）对合并报表范围内子 公司银行借款担保情况因业务进展发生了变动，现公告如下： 一、对外担保基本情况及进展 结合自身经营流动资金需求，经公司 2023 年年度股东大会决议，巴州晨光 植物蛋白有限公司（以下简称"巴州蛋白"，系新疆晨光生物科技股份有限公司 全资子公司，穿透后为公司控股子公司）前期向中国农业银行股份有限公司焉耆 回族自治县支行（以下简称"焉耆农行"）申请办理了 9,000 万元流动资金借款， 担保方式：公司保证担保。 公司与焉耆农行签署了《保证合同》，担保金额：9,000 万元；保证方式： 连带责任保证；保证期间为：主合同约定的债务履行期限届满之日起三年；保证 范围为：债务人在主合同项下应偿付的借款本金、利息、罚息、复利、违约金、 损害赔偿金、按规定确定由债务人和担保人承担的迟延履行债务利息和迟延履行 金、保全保险费以及诉讼（仲裁）费、律师费等债权人实现债权的一切费用（详 见 2024 年 12 月 23 日披露于巨潮资讯网的《关于为子公司银行借款提供担保的 进展公告》）。 截至公告披露日，巴州蛋白陆续归还了焉耆农行上述借款，公司减少了对应 的 9,00 ...

Core Viewpoint - The company, Morning Light Bio, is experiencing a decline in stock price and is undergoing a significant ownership change in one of its subsidiaries, which may impact its financial reporting and operations [1] Company Overview - Morning Light Bio focuses on the research, production, and sales of plant extracts, with applications in food, health products, and cosmetics [1] - Key products include capsanthin, lutein, and steviol glycosides, which are natural plant extracts [1] Recent Developments - On August 20, the company announced that its wholly-owned subsidiary, Hebei Morning Light Pharmaceutical, plans to transfer 97.5% of its stake in Hebei Morning Light Tianrun Pharmaceutical to Sichuan Tongsheng Biopharmaceutical [1] - Following the transfer, Morning Light Tianrun Pharmaceutical will no longer be included in the company's consolidated financial statements [1] - As of July 31, 2025, the company has a loan balance of 70.7824 million yuan to Morning Light Tianrun Pharmaceutical [1] Market Activity - On August 21, the stock price was reported at 13.67 yuan, reflecting a decrease of 1.87% from the previous trading day [1] - The trading volume for that day was 97,213 hands, with a transaction amount of 134 million yuan [1] - On the same day, the net inflow of main funds was 1.9326 million yuan, accounting for 0.04% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds reached 20.7632 million yuan, representing 0.38% of the circulating market value [1]

Policy Developments - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Physical Therapy Medical Services (Trial)" which integrates existing pricing projects into 32 items, with 7 additional charges and 1 expansion item [2] Medical Device Approvals - In July, the National Medical Products Administration approved 295 medical device products, including 240 domestic Class III devices, 21 imported Class III devices, 29 imported Class II devices, and 5 devices from Hong Kong, Macau, and Taiwan [4] Company Announcements - New Industries announced that 18 of its chemiluminescent reagent products received IVDR CE certification, allowing them to enter the EU market, which is expected to enhance the company's competitiveness [5] - Jining Pharmaceutical received a drug re-registration approval for hydrolyzed protein injection, which is used for severe amino acid deficiency and will help restore normal production and sales [6] - Chongqing Pharmaceutical Holdings reported a net profit of 282 million yuan for the first half of the year, with a revenue of 41.188 billion yuan, marking a 3.54% year-on-year increase [8] - Jimin Health reported a net loss of 52.6959 million yuan for the first half of 2025, with a revenue of 36.6 million yuan, down 21.30% year-on-year [9] - Chenguang Bio announced plans to transfer 97.5% of its subsidiary Chenguang Tianrun Pharmaceutical to Sichuan Tongsheng Biomedical, with the transfer based on the subsidiary's equity as of July 31, 2025 [11] - Baiyang Pharmaceutical's controlling shareholder plans to increase capital and change the shareholding structure, with a new entity set to acquire 80% of the controlling group [13] Industry Events - A groundbreaking cervical spine surgery was successfully performed in Shanghai, utilizing innovative "satellite steel plate" technology to stabilize a severely injured patient's spine [15] - Guangxi plans to provide free HPV vaccinations to nearly 960,000 eligible girls from 2025 to 2027, emphasizing the importance of preventive healthcare [16] Shareholder Actions - Multiple shareholders of Sanxin Medical plan to reduce their stakes in the company due to personal financial needs, with specific share amounts outlined for each individual [18]

晨光生物公告，全资子公司河北晨光药业拟以晨光天润制药截至2025年7月31日的账面股东权益为准将 持有的晨光天润制药97.5%股权转让给四川同晟生物医药有限公司。转让完成后，晨光天润制药将不再 纳入公司合并报表范围。截至2025年7月31日，公司（含其他子公司）向晨光天润制药提供借款余额为 7078.24万元。 ...

关于拟转让控股子公司股权暨被动形成财务资助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300138 证券简称：晨光生物 公告编号：2025—073 晨光生物科技集团股份有限公司 一、交易概述 1、晨光生物科技集团股份有限公司（以下简称"公司"或"晨光生物"） 全资子公司——河北晨光药业有限公司（以下简称"晨光药业"）持有河北晨光 天润制药有限公司（以下简称"晨光天润制药"）97.5%股权。 为优化资产结构，晨光药业拟以晨光天润制药截至 2025 年 7 月 31 日的账面 股东权益为准将持有的晨光天润制药 97.5%股权转让给四川同晟生物医药有限 公司（"同晟医药"）。本次股权转让完成后，晨光天润制药公司将不再是公司 合并报表范围内的子公司。 2025 年 8 月 18 日，晨光药业、晨光天润制药、同晟医药、公司实际控制人 卢庆国及同晟医药控股股东的关联人陈云虎签署了《股权转让协议》，《股权转 让协议》须经公司有权决策机构批准后生效。 2、本次转让事项不构成关联交易，也不构成《上市公司重大资产重组管理 办法》规定的重大资产重组。本次转让股 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600737 | 中粮糖业 | 12.62 | 10.03% | 76.42万 | 9.50亿 | | 000911 | 广农糖业 | 7.85 | 2.35% | 26.59万 | 2.11亿 | | 000930 | 中粮科技 | 6.10 | 0.66% | 53.91万 | 3.33亿 | | 666000E | 全龙鱼 | 31.72 | 0.60% | 32.10万 | 10.28亿 | | 300268 | *ST佳沃 | 10.45 | 0.58% | 1.98万 | 2084.26万 | | 000972 | *ST中基 | 3.62 | 0.28% | 18.55万 | 6700.65万 | | 600191 | 华资实业 | 8.00 | 0.25% | 12.21万 | 9862.28万 | | 300138 | 晨光生物 | 13.60 | 0.15% | 8.47万 | 1.15 Z | | 605198 | 安德利 | ...

Core Viewpoint - The company has been developing its industrial hemp business since 2019, establishing a production base in Tengchong, Yunnan, and obtaining necessary licenses for cultivation and processing [1] Company Overview - The company has acquired the "Industrial Hemp Cultivation License" and "Industrial Hemp Processing License," enabling it to engage in the entire process of cultivation, extraction, processing, and sales [1] - The company's industrial hemp extract products include high-purity CBD crystals (99%) and full-spectrum CBD oil (50%), among other specifications [1] Business Development - The industrial hemp business is currently in its early development stage, contributing less than 0.1% to the company's total revenue [1] - The company is closely monitoring domestic and international policies related to industrial hemp, indicating a proactive approach to market changes [1] - If downstream demand increases, the company plans to leverage its large-scale production capacity and significant cost advantages to capture market growth [1]

证券日报网讯晨光生物（300138）8月12日在互动平台回答投资者提问时表示，新疆是公司重要的原材 料产区之一，新藏铁路建设有利于新疆经济发展及区域稳定，为公司经营业务开展创造优质环境。 ...